Is Aptose Biosciences Inc. (APS.TO) a Buy, Sell, or Hold?
TSX : APS.TO
Aptose Biosciences Inc.
$2.4 CAD
$0 (0.0%)
- Volume
- 2.94K
- Average Volume
- 2.78K
- Market Capitalization
- $6.13M
- P/E Ratio
- -0.16
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.48
- Year Low
- $1.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.55
Company Overview
TSX
William G. Rice
Biotechnology
Healthcare
APS.TO
14
CA
CAD
Liquidity Metrics
0.00
0.55
0.55
0.09
0.00
Sales & Valuation
-$
0.00
-0.13
0.00
0.00
Profitability
-$10.59
-$25.91M
0.00%
0.00%
-23.18%
51.69%
P/E Metrics
-0.16
0.00
0.00
Analyst Price Target & Rating
0/5
11 Analysts
%
Poll Results
About Aptose Biosciences Inc. (TSX:APS.TO) Stock
Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's ... lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.
Frequently Asked Questions
-
What is the current Aptose Biosciences Inc. (APS.TO) stock price?
-
Aptose Biosciences Inc.(TSX:APS.TO) stock price is $2.4 in the last trading session. During the trading session, APS.TO stock reached the peak price of $2.48 while $1.41 was the lowest point it dropped to. The percentage change in APS.TO stock occurred in the recent session was 0.0% while the dollar amount for the price change in APS.TO stock was $0.
-
APS.TO's industry and sector of operation?
-
The TSX listed APS.TO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APS.TO?
-
William G. Rice | Chairman, President & Chief Executive Officer
Fletcher Payne | Senior Vice President, Chief Financial Officer, Chief Business Officer & Secretary
Rafael Bejar | Senior Vice President & Chief Medical Officer
|
| -
How many employees does APS.TO have?
-
Number of APS.TO employees currently stands at 14. APS.TO operates from 66 Wellington Street West, Toronto, ON M5K 1E6, CA.
-
Link for APS.TO official website?
-
Official Website of APS.TO is: https://www.aptose.com
-
How do I contact APS.TO?
-
APS.TO could be contacted at phone #16507185028 and can also be accessed through its website. APS.TO operates from 66 Wellington Street West, Toronto, ON M5K 1E6, CA.
-
How many shares of APS.TO are traded daily?
-
The average number of APS.TO shares traded daily for last 3 months was 2.78K.
-
What is the market cap of APS.TO currently?
-
The market value of APS.TO currently stands at $6.13M with its latest stock price at $2.4